A Physiologic Adaptive Radiation Therapy Pipeline for Glioblastoma by Daily Multiparametric MRI and Machine Learning
通过日常多参数 MRI 和机器学习治疗胶质母细胞瘤的生理适应性放射治疗流程
基本信息
- 批准号:10583517
- 负责人:
- 金额:$ 54.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-03 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAgreementAnatomyBiopsyBrainBrain NeoplasmsCellularityClassificationClinicalCollaborationsComputer softwareDataDetectionDevelopmentDevicesDiagnosticDiffusionDisabled PersonsDoseEarly identificationExcisionFutureGadoliniumGenerationsGlioblastomaGoalsGrowthHypoxiaImageImaging TechniquesInflammationInstitutionInstitutional Review BoardsInterventionKineticsLesionMachine LearningMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of brainManualsMapsMeasurementMetabolismMissionModelingMotionNational Cancer InstituteNewly DiagnosedOutcomePatient-Focused OutcomesPatientsPerfusionPeriodicalsPhasePhysiologicalPhysiologyPilot ProjectsPreparationProcessPrognosisProtocols documentationRadiation therapyResearchScanningSpectrum AnalysisSystemTechniquesTestingTranslatingTumor VolumeValidationWorkautomated segmentationchemotherapyclinical translationdeep learningdesignhigh riskimage processingimprovedindustry partnerinnovationmemberneovascularizationneuroimagingperfusion imagingprospectivequantitative imagingradiomicsresponsetemozolomidetreatment responsetrendtumortumor growthvalidation studies
项目摘要
Project Summary/Abstract
Glioblastoma is the most common cancer originating in the brain with ~12,000 new diagnoses
per year in the U.S.A. and median survival about 18 months. A common dilemma for the patient
and treatment team is that the clinical MRI one month after radiation therapy (RT) shows
growth of unclear significance in up to 50% of patients. Patients with true progression (TP) of
non-responding tumor continue to progress on serial MRIs and usually die within 9 months. TP
is usually determined 6 or more months after completion of RT, often when it is too late to
intervene. The mission of the National Cancer Institute is to improve survival of patients with
cancer. Our goal, and an unmet need, is to identify glioblastoma patients with TP early during
treatment and implement aggressive second-line therapy to improve survival.
This proposal describes an innovative approach to identify early glioblastoma TP by improving
neuroimaging and image processing on MRIdian, a new combination MRI and RT (MRI-RT)
device from ViewRay, Inc where patients undergo MRI daily as part of their RT. Our preliminary
data with MRIdian is the first to demonstrate daily glioblastoma growth on MRI in patients
during RT. By developing physiologic MRI techniques on MRIdian (Aim 1), we seek to identify
TP when there is growth during RT (Aim 2), and intensify RT to that TP (Aim 3/future).
The most sensitive and specific commonly applied clinical MRI techniques for identifying TP
after RT correlate with tumor physiology: diffusion (cellularity), perfusion (hypoxia), and
spectroscopy (metabolism). These are collectively termed mpMRI. The hypothesis of aim 1 is
that the academic-industrial partnership between Miami and ViewRay can develop mpMRI for
daily measurements during RT on MRIdian. The hypothesis of aim 2 is that the images from
daily mpMRI during MRI-RT in glioblastoma patients can be processed by machine learning
and radiomics techniques to automatically detect glioblastoma growth and predict long-term
outcome. Aim 3 then combines aims 1-2 to test a prospective workflow to intensify RT to TP
when TP is first identified during RT based on mpMRI elucidated trends in tumor physiology, so
called “physiologic adaptive RT” (PART).
The PART workflow will be developed by Miami and Viewray and integrated into MRIdian. The
advantage of using single platform MRIdian is that the PART workflow will be distributed by
Viewray to the over 60 MRIdian centers. This easy clinical translation will permit us to proceed
with multi-institutional trials of early RT dose escalation to improve survival of poorly
responding glioblastomas.
项目摘要/摘要
胶质母细胞瘤是最常见的起源于大脑的癌症,新诊断约12,000例
每年在美国,中位生存期约为18个月。患者面临的一个常见困境
而治疗小组则是放射治疗(RT)后一个月的临床MRI显示
高达50%的患者出现意义不明的生长。真正进展(TP)的患者
无反应的肿瘤继续在系列磁共振成像上进展,通常在9个月内死亡。总磷
通常在RT完成后6个月或更长时间确定,通常在为时已晚时
进行干预。国家癌症研究所的使命是提高患有癌症的患者的存活率
癌症。我们的目标,也是一个未得到满足的需求,是在早期发现患有TP的胶质母细胞瘤患者。
治疗和实施积极的二线治疗以提高存活率。
这项建议描述了一种创新的方法来识别早期胶质母细胞瘤TP通过改进
一种新的MRI与RT(MRI-RT)结合的MRIdian的神经成像和图像处理
来自ViewRay,Inc.的设备,患者每天在那里接受核磁共振检查,作为其RT的一部分。我们的预赛
MRIdian的数据第一次在患者的MRI上显示了胶质母细胞瘤的日常生长
在RT期间。通过在MRIdian(目标1)上开发生理学MRI技术,我们试图识别
在RT过程中有生长时进行TP(目标2),并加强对TP的RT(目标3/将来)。
临床上最敏感、最特异的诊断TP的MRI技术
放疗后与肿瘤生理相关:扩散(细胞性)、灌注性(缺氧)和
光谱学(代谢)。这些统称为mpMRI。目标1的假设是
迈阿密和ViewRay之间的学术-产业合作伙伴关系可以为
在MRIdian上RT期间的每日测量。目标2的假设是来自
胶质母细胞瘤患者在MRI-RT期间的日常mpMRI可以通过机器学习进行处理
和放射组学技术,自动检测胶质母细胞瘤的生长并预测长期
结果。然后,目标3结合目标1-2来测试预期的工作流,以将RT强化到TP
当基于mpMRI的放射治疗中首次发现TP时,阐明了肿瘤生理学的趋势,因此
称为“生理适应性RT”(部分)。
零件工作流程将由迈阿密和ViewRay开发,并集成到MRIdian中。这个
使用单一平台MRIdian的优势在于,部件工作流将通过
向60多个核磁共振成像中心发送ViewRay。这一简单的临床翻译将允许我们继续进行
早期RT剂量递增的多机构试验以改善不良患者的存活率
有反应性的胶质母细胞瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eric Albert Mellon其他文献
Eric Albert Mellon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eric Albert Mellon', 18)}}的其他基金
A Physiologic Adaptive Radiation Therapy Pipeline for Glioblastoma by Daily Multiparametric MRI and Machine Learning
通过日常多参数 MRI 和机器学习治疗胶质母细胞瘤的生理适应性放射治疗流程
- 批准号:
10446236 - 财政年份:2022
- 资助金额:
$ 54.61万 - 项目类别:
CLINICAL LACTATE IMAGING BY LACTATE SELECTIVE SPECTROSCOPY
通过乳酸选择性光谱进行临床乳酸成像
- 批准号:
8361957 - 财政年份:2011
- 资助金额:
$ 54.61万 - 项目类别:
CLINICAL LACTATE IMAGING BY LACTATE SELECTIVE SPECTROSCOPY
通过乳酸选择性光谱进行临床乳酸成像
- 批准号:
8169043 - 财政年份:2010
- 资助金额:
$ 54.61万 - 项目类别:
CLINICAL LACTATE IMAGING BY LACTATE SELECTIVE SPECTROSCOPY
通过乳酸选择性光谱进行临床乳酸成像
- 批准号:
7955317 - 财政年份:2009
- 资助金额:
$ 54.61万 - 项目类别:
SODIUM MRI OF THE BRAIN OF PATIENTS WITH ALZHEIMER?S DISEASE
阿尔茨海默病患者脑部的钠 MRI
- 批准号:
7955313 - 财政年份:2009
- 资助金额:
$ 54.61万 - 项目类别:
CLINICAL LACTATE IMAGING BY LACTATE SELECTIVE SPECTROSCOPY
通过乳酸选择性光谱进行临床乳酸成像
- 批准号:
7723816 - 财政年份:2008
- 资助金额:
$ 54.61万 - 项目类别:
Assessment of cerebral metabolism in vivo by 17-Oxygen magnetic resonance imaging
17-氧磁共振成像评估体内脑代谢
- 批准号:
8063482 - 财政年份:2008
- 资助金额:
$ 54.61万 - 项目类别:
SODIUM MRI OF THE BRAIN OF PATIENTS WITH ALZHEIMER?S DISEASE
阿尔茨海默病患者脑部的钠 MRI
- 批准号:
7723812 - 财政年份:2008
- 资助金额:
$ 54.61万 - 项目类别:
Assessment of cerebral metabolism in vivo by 17-Oxygen magnetic resonance imaging
17-氧磁共振成像评估体内脑代谢
- 批准号:
7409321 - 财政年份:2008
- 资助金额:
$ 54.61万 - 项目类别:
SODIUM MRI OF THE BRAIN OF PATIENTS WITH ALZHEIMER?S DISEASE
阿尔茨海默病患者脑部的钠 MRI
- 批准号:
7600825 - 财政年份:2007
- 资助金额:
$ 54.61万 - 项目类别:
相似海外基金
A study for cross borders Indonesian nurses and care workers: Case of Japan-Indonesia Economic Partnership Agreement
针对跨境印度尼西亚护士和护理人员的研究:日本-印度尼西亚经济伙伴关系协定的案例
- 批准号:
22KJ0334 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Grant-in-Aid for JSPS Fellows
NSF-NOAA Interagency Agreement (IAA) for the Global Oscillations Network Group (GONG)
NSF-NOAA 全球振荡网络组 (GONG) 机构间协议 (IAA)
- 批准号:
2410236 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Cooperative Agreement
Conditions for U.S. Agreement on the Closure of Contested Overseas Bases: Relations of Threat, Alliance and Base Alternatives
美国关于关闭有争议的海外基地协议的条件:威胁、联盟和基地替代方案的关系
- 批准号:
23K18762 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
MSI Smart Manufacturing Data Hub – Open Calls Grant Funding Agreement
MSI 智能制造数据中心 – 公开征集赠款资助协议
- 批准号:
900240 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Collaborative R&D
Challenges of the Paris Agreement Exposed by the Energy Shift by External Factors: The Case of Renewable Energy Policies in Japan, the U.S., and the EU
外部因素导致的能源转移对《巴黎协定》的挑战:以日本、美国和欧盟的可再生能源政策为例
- 批准号:
23H00770 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Continuation of Cooperative Agreement between U.S. Food and Drug Administration and S.C. Department of Health and Environmental Control (DHEC) for MFRPS Maintenance.
美国食品和药物管理局与南卡罗来纳州健康与环境控制部 (DHEC) 继续签订 MFRPS 维护合作协议。
- 批准号:
10829529 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
National Ecological Observatory Network Governing Cooperative Agreement
国家生态观测站网络治理合作协议
- 批准号:
2346114 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Cooperative Agreement
The Kansas Department of Agriculture's Flexible Funding Model Cooperative Agreement for MFRPS Maintenance, FPTF, and Special Project.
堪萨斯州农业部针对 MFRPS 维护、FPTF 和特别项目的灵活资助模式合作协议。
- 批准号:
10828588 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Robust approaches for the analysis of agreement between clinical measurements: development of guidance and software tools for researchers
分析临床测量之间一致性的稳健方法:为研究人员开发指南和软件工具
- 批准号:
MR/X029301/1 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Linguistic transfer in a contact variety of Spanish: Gender agreement production and attitudes
博士论文研究:西班牙语接触变体中的语言迁移:性别协议的产生和态度
- 批准号:
2234506 - 财政年份:2023
- 资助金额:
$ 54.61万 - 项目类别:
Standard Grant